{"id":14325,"date":"2020-08-25T21:07:54","date_gmt":"2020-08-25T21:07:54","guid":{"rendered":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/?p=14325"},"modified":"2021-12-24T11:17:57","modified_gmt":"2021-12-24T11:17:57","slug":"what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare","status":"publish","type":"post","link":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\/","title":{"rendered":"What Needs to Happen for Polygenic Risk Scores (PRS) to be Routinely Used in Healthcare?"},"content":{"rendered":"

The\u00a0Predictive Genomics<\/a>\u00a0blog series provides perspectives on the use and impact of genetic risk screening & pharmacogenomics in clinical research. Predictive Genomics is powerful capability to study disease risk and understand drug response in order to focus health care resources on improving outcomes and managing costs. To talk with our team on implementing your genetic-based initiatives, please\u00a0contact us<\/a>\u00a0or browse our\u00a0predictive genomics solutions<\/a>.<\/em><\/p>\n

\"DNA<\/p>\n

Polygenic risk scores (PRS\u2019s) are a type of genetic test in which dozens to millions of low-impact genetic variants are identified and mathematically combined to produce a \u201crisk\u201d score for a specific health condition (eg, Type 2 Diabetes or Schizophrenia) or phenotypic feature (eg, height).\u00a0 In the scientific literature, the resulting score is typically presented as an odds ratio.<\/p>\n

If a PRS is making a health-related claim, it requires all the same evidence that is required of any other clinical test before it can be legally marketed. Similarly, a PRS\u2019s path to widespread adoption will be the same as for other clinical tests. In this blog we will review the data necessary for a clinical test to be legally marketed, the routes to market, and the data needed for payers and providers to make decisions about coverage and use. We will discuss why it is a formidable challenge to apply this evidentiary framework to PRS\u2019s and elucidate why no PRS\u2019s have achieved widespread usage or coverage to date.<\/p>\n

What Types of Pre-Market Studies are Required for Clinical Tests?<\/strong><\/h2>\n

The two main requirements for legally marketing a clinical test are analytical validity and clinical validity. Tables 1 and 2.<\/p>\n\n\n\n\n\n\n\n
<\/td>\nAnalytical Validity<\/td>\nClinical Validity<\/td>\n<\/tr>\n
Purpose<\/td>\nQuantifies the test\u2019s ability to detect what it says it detects.<\/td>\nQuantifies the test\u2019s ability to detect a disease or condition.<\/td>\n<\/tr>\n
Examples<\/td>\nDetection of a nucleic acid base change from A>G in DNA.<\/p>\n

 <\/p>\n

Detection of a protein fragment from the HHV-8 virus in blood.<\/td>\n

People with dysfunctional NF1 genes have Neurofibromatosis Type 1.<\/p>\n

 <\/p>\n

People with HHV-8 have ____ disease.<\/td>\n<\/tr>\n

Definition<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Outputs<\/td>\nAnalytical sensitivity<\/p>\n

Analytical specificity<\/p>\n

Reliability<\/p>\n

Reproducibility<\/p>\n

Interfering substances<\/p>\n

Limit of detection<\/p>\n

 <\/td>\n

Clinical sensitivity<\/p>\n

Clinical specificity<\/p>\n

Positive predictive value<\/p>\n

Negative predictive value<\/p>\n

Likelihood ratios<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Study Designs for Establishing Analytical and Clinical Validity<\/strong><\/h2>\n

Both are based on the classic 2 x 2 table that compares the performance of the new test (the index test) to the reference standard. The output metrics for each are mathematical calculations from the 2 x 2 table and are well-described in the medical and statistical literature. (REFS)<\/p>\n\n\n\n\n\n\n
\n

ANALYTICAL VALIDATION STUDY DESIGN<\/strong><\/p>\n<\/td>\n<\/tr>\n

<\/td>\nSamples known to have the analytic change of interest as determined by reference standard<\/td>\nSamples known NOT to have the analytic change of interest as determined by reference standard<\/td>\n<\/tr>\n
Samples positive for the analyte change by NEW TEST<\/td>\nTrue Positives<\/td>\nFalse Positives<\/td>\n<\/tr>\n
Samples negative for the analyte change by NEW TEST<\/td>\nFalse Negatives<\/td>\nTrue Negatives<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n
\n

CLINICAL VALIDATION STUDY DESIGN<\/strong><\/p>\n<\/td>\n<\/tr>\n

<\/td>\nSamples from individuals known to have the condition of interest as determined by reference standard<\/td>\nSamples individuals known NOT to have the condition of interest as determined by reference standard<\/td>\n<\/tr>\n
Samples positive for the condition by NEW TEST<\/td>\nTrue Positives<\/td>\nFalse Positives<\/td>\n<\/tr>\n
Samples negative for the condition by NEW TEST<\/td>\nFalse Negatives<\/td>\nTrue Negatives<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Regulatory Routes in the United States<\/strong><\/h2>\n

The more complex question in the United States is which regulatory route a test developer chooses to take to get their test on the market. There are two federal agencies and two separate regulations: The Food and Drug Administration (FDA) regulations are based on the laws set forth in the Tobacco Control Act and the Food, Drug, and Cosmetic Act (FD&C Act) and the Center for Medicare and Medicaid (CMS) with regulations based on CLIA\u201988.<\/p>\n

The US Food and Drug Administration (FDA) claims jurisdiction for all medical devices, including in vitro diagnostics (IVDs). The objective is to offer assurance that a test performs robustly enough for clinical decision-making and that the associated clinical claims are valid. Classic IVDs are test kits (ie, pre-measured reagents and the directions for how to combine them) that are produced in a manufacturing plant and sold to credentialed clinical labs via interstate commerce. Once the manufacturer develops the intended use statement, they are required to submit data showing both the analytical validity of the test and clinical validity of the claim to the FDA before marketing the kit to clinical laboratories. Once purchased, the performance metrics of the test are verified by the local clinical lab and the test is made available for physicians to order. (See verified vs validated<\/a>). The premarket review process makes it relatively expensive (due to both fees and personnel costs), delays time to market, and stifles innovation and improvement of previously submitted products because amendments are expensive and time-consuming.<\/p>\n

However, some laboratories have adopted a different path for clinical tests called a\u00a0laboratory developed test (LDT)<\/a>. One example is Dutch molecular diagnostics firm SkylineDx that offers laboratory developed tests for multiple myeloma and acute myeloid leukemia, called MMprofiler and AMLprofiler, both of which run on Thermo Fisher Scientific\u2019s microarrays. Their new melanoma test<\/a> based on Thermo Fisher QuantStudio 5 quantitative PCR platform will also be offered as an LDT in the US, possibly paving the way for a CE-IVD test next year.<\/p>\n

According to the FDA<\/a>, an LDT is a type of IVD that also falls under their jurisdiction. This is contested by many laboratory professional entities. Historically, the FDA has exercised \u201cenforcement discretion\u201d with LDTs, i.e. they only intervene and require pre-market review when the laboratory\/manufacturer of the LDT is marketing a product that does not have sufficient analytical and clinical evidence to be on market.<\/p>\n

Although CLIA only requires laboratories to demonstrate analytical validity before marketing a test, in practice, all credible laboratories also document the clinical validity of the claim. Well-trained health professionals operate with patient safety as the priority. Besides, why spend the money to develop a test that isn\u2019t clinically valid? Recently, however, there has been an increase in the number of investor-backed clinical laboratories where decision-making authority is given to individuals without proper education and training in clinical laboratory medicine. Investor\u2019s needs rival or supersede patient safety as the guiding principle and tests without evidence to support the clinical claim are marketed to physicians or consumers. This is why some people think that all LDTs should be regulated like IVDs and undergo pre-market review by the FDA. In the end, if the claims about the clinical meaning of your LDT does not have clinical validity, the agency will retract its enforcement discretion, pull your product from the market, and require you to submit the necessary data for your LDT to the FDA prior to returning to the market.<\/p>\n

The takeaway is that all clinical tests are required to demonstrate analytical and clinical validity before they are marketed for clinical use, and the same applies to PRS\u2019s making a health claim. The route to market is the more complex question.\u00a0<\/strong><\/p>\n

How Does a PRS-based Test Achieve Widespread Adoption?<\/strong><\/h2>\n

Regulatory bodies care primarily about the analytical and clinical validity of the test. Payers and providers care primarily about the clinical utility and cost-effectiveness of the recommended intervention based on the results of the test.<\/p>\n

Clinical validity quantitates the strength of the association between the analytical change detected and the clinical condition of interest. But, is knowing that clinically useful? What will doctors do with that information? Is it more or less useful than the standard of care? This is called clinical utility<\/em> and payers and providers expect this question to be answered before they cover or adopt a new test. To date, there are no published clinical utility studies for claims made based on a PRS.<\/p>\n

Clinical utility <\/em>studies test the safety and efficacy of an intervention based on the PRS test result versus current standard of care. For example,<\/p>\n

    \n
  • Men over 40 identified by PRS of being in top 3% of CAD event risk who take a statin will have a lower percentage of CAD events than men over 40 identified as being in the top 3% risk by clinical risk score who are put on statins.<\/li>\n
  • Individuals In the top decile of CAD PRS have the same risk of CAD as individuals with monogenic FH (clinical validity claim) and should be managed the same as FH (clinical utility claim).<\/li>\n<\/ul>\n

     <\/p>\n

    What about the economics of the new test and its intervention? Does this cost a huge amount of money for a negligible or no real health benefit? Payers and providers also expect to have an understanding of the economic factors before making a coverage or adoption decision. (Looking into the future)<\/p>\n

    The types of studies required by regulatory agencies to assess if a test is appropriate for clinical use and the types of studies required by payers and providers to make coverage or adoption decisions are well-known. For polygenic risk scores to achieve widespread clinical adoption, each one will need to undergo the same studies expected of all clinical tests. The choice of regulatory path may also impact the time to market and the ability to iterate to improve both quality and cost of testing.<\/p>\n

    \u00a0<\/strong><\/p>\n

    \u00a0<\/strong><\/p>\n

    \u00a0<\/strong><\/p>\n

    \u00a0<\/strong><\/p>\n

     <\/p>\n

     <\/p>\n","protected":false},"excerpt":{"rendered":"

    The\u00a0Predictive Genomics\u00a0blog series provides perspectives on the use and impact of genetic risk screening & pharmacogenomics in clinical research. Predictive Genomics is powerful capability to study disease risk and understand drug response in order to focus health care resources on improving outcomes and managing costs. To talk with our team on implementing your genetic-based initiatives,<\/p>\n","protected":false},"author":120,"featured_media":14328,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_monsterinsights_skip_tracking":false,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[172],"tags":[1507],"division":[],"class_list":{"0":"post-14325","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-general","8":"tag-predictive-genomics","9":"entry"},"_selected_authors":"","_selected_reviewers":"","acf":[],"yoast_head":"\nWhat Needs to Happen for Polygenic Risk Scores (PRS) to be Routinely Used in Healthcare? - Behind the Bench<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.thermofisher.com\/blog\/behindthebench\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"What Needs to Happen for Polygenic Risk Scores (PRS) to be Routinely Used in Healthcare?\" \/>\n<meta property=\"og:description\" content=\"The\u00a0Predictive Genomics\u00a0blog series provides perspectives on the use and impact of genetic risk screening & pharmacogenomics in clinical research. Predictive Genomics is powerful capability to study disease risk and understand drug response in order to focus health care resources on improving outcomes and managing costs. To talk with our team on implementing your genetic-based initiatives,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.thermofisher.com\/blog\/behindthebench\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\/\" \/>\n<meta property=\"og:site_name\" content=\"Behind the Bench\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/thermofisher\" \/>\n<meta property=\"article:published_time\" content=\"2020-08-25T21:07:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-24T11:17:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2020\/08\/AV1354-001-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2527\" \/>\n\t<meta property=\"og:image:height\" content=\"2560\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Behind The Bench Staff\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@thermofisher\" \/>\n<meta name=\"twitter:site\" content=\"@thermofisher\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Behind The Bench Staff\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/behindthebench\\\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/behindthebench\\\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\\\/\"},\"author\":{\"name\":\"Behind The Bench Staff\",\"@id\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/behindthebench\\\/#\\\/schema\\\/person\\\/9bbb2d67616274d3d4a21a584f7f4a0c\"},\"headline\":\"What Needs to Happen for Polygenic Risk Scores (PRS) to be Routinely Used in Healthcare?\",\"datePublished\":\"2020-08-25T21:07:54+00:00\",\"dateModified\":\"2021-12-24T11:17:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/behindthebench\\\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\\\/\"},\"wordCount\":1539,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/behindthebench\\\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/behindthebench\\\/wp-content\\\/uploads\\\/sites\\\/9\\\/2020\\\/08\\\/AV1354-001-scaled.jpg\",\"keywords\":[\"predictive genomics\"],\"articleSection\":[\"General\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/behindthebench\\\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/behindthebench\\\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\\\/\",\"url\":\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/behindthebench\\\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\\\/\",\"name\":\"What Needs to Happen for Polygenic Risk Scores (PRS) to be Routinely Used in Healthcare? - Behind the Bench\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/behindthebench\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/behindthebench\\\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/behindthebench\\\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/behindthebench\\\/wp-content\\\/uploads\\\/sites\\\/9\\\/2020\\\/08\\\/AV1354-001-scaled.jpg\",\"datePublished\":\"2020-08-25T21:07:54+00:00\",\"dateModified\":\"2021-12-24T11:17:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/behindthebench\\\/#\\\/schema\\\/person\\\/9bbb2d67616274d3d4a21a584f7f4a0c\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/behindthebench\\\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/behindthebench\\\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/behindthebench\\\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/behindthebench\\\/wp-content\\\/uploads\\\/sites\\\/9\\\/2020\\\/08\\\/AV1354-001-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/behindthebench\\\/wp-content\\\/uploads\\\/sites\\\/9\\\/2020\\\/08\\\/AV1354-001-scaled.jpg\",\"width\":2527,\"height\":2560},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/behindthebench\\\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/behindthebench\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"What Needs to Happen for Polygenic Risk Scores (PRS) to be Routinely Used in Healthcare?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/behindthebench\\\/#website\",\"url\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/behindthebench\\\/\",\"name\":\"Behind the Bench\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/behindthebench\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/behindthebench\\\/#\\\/schema\\\/person\\\/9bbb2d67616274d3d4a21a584f7f4a0c\",\"name\":\"Behind The Bench Staff\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/52d5c16ece4bd1c0a49a63521c2b6a25c54a3f0c33f7afed215ba7e0cdff69e3?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/52d5c16ece4bd1c0a49a63521c2b6a25c54a3f0c33f7afed215ba7e0cdff69e3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/52d5c16ece4bd1c0a49a63521c2b6a25c54a3f0c33f7afed215ba7e0cdff69e3?s=96&d=mm&r=g\",\"caption\":\"Behind The Bench Staff\"},\"url\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/author\\\/behind-the-bench-staff\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"What Needs to Happen for Polygenic Risk Scores (PRS) to be Routinely Used in Healthcare? - Behind the Bench","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\/","og_locale":"en_US","og_type":"article","og_title":"What Needs to Happen for Polygenic Risk Scores (PRS) to be Routinely Used in Healthcare?","og_description":"The\u00a0Predictive Genomics\u00a0blog series provides perspectives on the use and impact of genetic risk screening & pharmacogenomics in clinical research. Predictive Genomics is powerful capability to study disease risk and understand drug response in order to focus health care resources on improving outcomes and managing costs. To talk with our team on implementing your genetic-based initiatives,","og_url":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\/","og_site_name":"Behind the Bench","article_publisher":"https:\/\/www.facebook.com\/thermofisher","article_published_time":"2020-08-25T21:07:54+00:00","article_modified_time":"2021-12-24T11:17:57+00:00","og_image":[{"width":2527,"height":2560,"url":"https:\/\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2020\/08\/AV1354-001-scaled.jpg","type":"image\/jpeg"}],"author":"Behind The Bench Staff","twitter_card":"summary_large_image","twitter_creator":"@thermofisher","twitter_site":"@thermofisher","twitter_misc":{"Written by":"Behind The Bench Staff","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\/#article","isPartOf":{"@id":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\/"},"author":{"name":"Behind The Bench Staff","@id":"https:\/\/admin.acceleratingscience.com\/behindthebench\/#\/schema\/person\/9bbb2d67616274d3d4a21a584f7f4a0c"},"headline":"What Needs to Happen for Polygenic Risk Scores (PRS) to be Routinely Used in Healthcare?","datePublished":"2020-08-25T21:07:54+00:00","dateModified":"2021-12-24T11:17:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\/"},"wordCount":1539,"commentCount":0,"image":{"@id":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\/#primaryimage"},"thumbnailUrl":"https:\/\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2020\/08\/AV1354-001-scaled.jpg","keywords":["predictive genomics"],"articleSection":["General"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.thermofisher.com\/blog\/behindthebench\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\/","url":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\/","name":"What Needs to Happen for Polygenic Risk Scores (PRS) to be Routinely Used in Healthcare? - Behind the Bench","isPartOf":{"@id":"https:\/\/admin.acceleratingscience.com\/behindthebench\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\/#primaryimage"},"image":{"@id":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\/#primaryimage"},"thumbnailUrl":"https:\/\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2020\/08\/AV1354-001-scaled.jpg","datePublished":"2020-08-25T21:07:54+00:00","dateModified":"2021-12-24T11:17:57+00:00","author":{"@id":"https:\/\/admin.acceleratingscience.com\/behindthebench\/#\/schema\/person\/9bbb2d67616274d3d4a21a584f7f4a0c"},"breadcrumb":{"@id":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.thermofisher.com\/blog\/behindthebench\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\/#primaryimage","url":"https:\/\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2020\/08\/AV1354-001-scaled.jpg","contentUrl":"https:\/\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2020\/08\/AV1354-001-scaled.jpg","width":2527,"height":2560},{"@type":"BreadcrumbList","@id":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/what-needs-to-happen-for-polygenic-risk-score-prs-to-be-routinely-used-in-healthcare\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admin.acceleratingscience.com\/behindthebench\/"},{"@type":"ListItem","position":2,"name":"What Needs to Happen for Polygenic Risk Scores (PRS) to be Routinely Used in Healthcare?"}]},{"@type":"WebSite","@id":"https:\/\/admin.acceleratingscience.com\/behindthebench\/#website","url":"https:\/\/admin.acceleratingscience.com\/behindthebench\/","name":"Behind the Bench","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admin.acceleratingscience.com\/behindthebench\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/admin.acceleratingscience.com\/behindthebench\/#\/schema\/person\/9bbb2d67616274d3d4a21a584f7f4a0c","name":"Behind The Bench Staff","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/52d5c16ece4bd1c0a49a63521c2b6a25c54a3f0c33f7afed215ba7e0cdff69e3?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/52d5c16ece4bd1c0a49a63521c2b6a25c54a3f0c33f7afed215ba7e0cdff69e3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/52d5c16ece4bd1c0a49a63521c2b6a25c54a3f0c33f7afed215ba7e0cdff69e3?s=96&d=mm&r=g","caption":"Behind The Bench Staff"},"url":"https:\/\/admin.acceleratingscience.com\/author\/behind-the-bench-staff\/"}]}},"taxonomy_info":{"category":[{"value":172,"label":"General"}],"post_tag":[{"value":1507,"label":"predictive genomics"}]},"featured_image_src_large":["https:\/\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2020\/08\/AV1354-001-1011x1024.jpg",760,770,true],"author_info":{"display_name":"Behind The Bench Staff","author_link":"https:\/\/admin.acceleratingscience.com\/author\/behind-the-bench-staff\/"},"comment_info":0,"category_info":[{"term_id":172,"name":"General","slug":"general","term_group":0,"term_taxonomy_id":172,"taxonomy":"category","description":"","parent":0,"count":160,"filter":"raw","meta":[],"cat_ID":172,"category_count":160,"category_description":"","cat_name":"General","category_nicename":"general","category_parent":0}],"tag_info":[{"term_id":1507,"name":"predictive genomics","slug":"predictive-genomics","term_group":0,"term_taxonomy_id":1507,"taxonomy":"post_tag","description":"","parent":0,"count":20,"filter":"raw","meta":[]}],"jetpack-related-posts":[{"id":20004,"url":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/a-guide-to-nucleic-acid-quality-control-dna-and-rna-purity\/","url_meta":{"origin":14325,"position":0},"title":"A Guide to Nucleic Acid Quality Control: DNA and RNA Purity","author":"Marlene Gasdia-Cochrane","date":"September 22, 2026","format":false,"excerpt":"Article Summary Nucleic acid quality control helps researchers evaluate DNA and RNA concentration and purity before downstream applications such as PCR, qPCR, and next-generation sequencing (NGS). A standardized workflow combining reliable extraction, concentration and purity assessment, application-appropriate quantification, and consistent laboratory practices can help identify sample issues early, improve reproducibility,\u2026","rel":"","context":"In "General"","block_context":{"text":"General","link":"https:\/\/admin.acceleratingscience.com\/behindthebench\/general\/"},"img":{"alt_text":"Close-up shot of a dna sequence on a screen, a digital representation of genetic code, used for analysis.","src":"https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/09\/iStock-2212923489_dnasequence-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/09\/iStock-2212923489_dnasequence-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/09\/iStock-2212923489_dnasequence-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/09\/iStock-2212923489_dnasequence-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/09\/iStock-2212923489_dnasequence-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/09\/iStock-2212923489_dnasequence-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":19883,"url":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/building-a-better-sample-qc-workflow-from-extraction-to-sequencing\/","url_meta":{"origin":14325,"position":1},"title":"Building a Better Sample QC Workflow: From Extraction to Sequencing","author":"Marlene Gasdia-Cochrane","date":"August 25, 2026","format":false,"excerpt":"Article Summary Successful genomics experiments don't begin with sequencing\u2014they begin with sample quality. Every downstream application, from PCR to next-generation sequencing (NGS), depends on starting with nucleic acids that are accurately quantified and free from contaminants that could compromise results. Establishing a consistent quality control workflow helps laboratories improve reproducibility\u2026","rel":"","context":"In "General"","block_context":{"text":"General","link":"https:\/\/admin.acceleratingscience.com\/behindthebench\/general\/"},"img":{"alt_text":"A pipette drops a liquid into a petri dish with a dna sequence background, science concept. It suggests medical or genetic research.","src":"https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/08\/iStock-2216731026_petridish-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/08\/iStock-2216731026_petridish-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/08\/iStock-2216731026_petridish-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/08\/iStock-2216731026_petridish-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/08\/iStock-2216731026_petridish-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/08\/iStock-2216731026_petridish-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":19857,"url":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/mirna-biomarkers-type-1-diabetes\/","url_meta":{"origin":14325,"position":2},"title":"A pan-continental miRNA profiling study powered by TaqMan qPCR reveals potential new biomarkers for Type 1 Diabetes risk","author":"Ashleigh Barlow","date":"July 28, 2026","format":false,"excerpt":"In conversation with Professor Anandwardhan Hardikar Detecting type 1 diabetes (T1D) before major pancreatic damage occurs remains one of the biggest challenges in the field. By the time most patients are diagnosed, a large proportion of insulin-producing islet \u03b2-cells have already been lost. Traditional markers such as blood glucose or\u2026","rel":"","context":"In "Complex Diseases"","block_context":{"text":"Complex Diseases","link":"https:\/\/admin.acceleratingscience.com\/behindthebench\/complex-diseases\/"},"img":{"alt_text":"Professor Anandwardhan Hardikar discussing type 1 diabetes biomarker research in front of molecular biology data visualizations.","src":"https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/07\/hardikar_Lisa-Crawford.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/07\/hardikar_Lisa-Crawford.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/07\/hardikar_Lisa-Crawford.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/07\/hardikar_Lisa-Crawford.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/07\/hardikar_Lisa-Crawford.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/07\/hardikar_Lisa-Crawford.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":19235,"url":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/crispr-digital-pcr-gene-editing-workflow\/","url_meta":{"origin":14325,"position":3},"title":"Revolutionizing Gene Editing with CRISPR and Digital PCR – A Conversation with Dr. Dustin Rubinstein","author":"Behind The Bench Staff","date":"November 11, 2025","format":false,"excerpt":"In a recent Absolute Gene-ius podcast episode titled \u201cCRISPR, dPCR, and pigs - a cut above the rest\u201d, Dr. Dustin Rubinstein, Director of the Advanced Genome Editing Laboratory at the University of Wisconsin-Madison, shared his insights on how CRISPR and digital PCR (dPCR) are revolutionizing gene editing workflows. This Q&A\u2026","rel":"","context":"In "Cancer Research"","block_context":{"text":"Cancer Research","link":"https:\/\/admin.acceleratingscience.com\/behindthebench\/cancer-research\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2025\/11\/S3-E1-Header-Image-1_Jordan-Ruggieri-scaled.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2025\/11\/S3-E1-Header-Image-1_Jordan-Ruggieri-scaled.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2025\/11\/S3-E1-Header-Image-1_Jordan-Ruggieri-scaled.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2025\/11\/S3-E1-Header-Image-1_Jordan-Ruggieri-scaled.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2025\/11\/S3-E1-Header-Image-1_Jordan-Ruggieri-scaled.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2025\/11\/S3-E1-Header-Image-1_Jordan-Ruggieri-scaled.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":19997,"url":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/ai-laboratory-automation-qpcr\/","url_meta":{"origin":14325,"position":4},"title":"AI and Laboratory Automation: The experimental context behind qPCR data","author":"Behind The Bench Staff","date":"September 11, 2026","format":false,"excerpt":"AI is changing how researchers analyze biological data, while automation is changing how that data is performed at scale. As more of the research process becomes automated and data-driven, an important question emerges: What should researchers consider about how data is generated before downstream analysis begins? In qPCR, assays, reagents,\u2026","rel":"","context":"In "Lab Tips and Tricks"","block_context":{"text":"Lab Tips and Tricks","link":"https:\/\/admin.acceleratingscience.com\/behindthebench\/lab-tips-and-tricks\/"},"img":{"alt_text":"qPCR reaction tube with amplification curves representing experimental data used in AI and laboratory automation.","src":"https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/09\/qPCR_GEN_Blog_AI_Lab_Automation_Amafel-Calalay.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/09\/qPCR_GEN_Blog_AI_Lab_Automation_Amafel-Calalay.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/09\/qPCR_GEN_Blog_AI_Lab_Automation_Amafel-Calalay.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/09\/qPCR_GEN_Blog_AI_Lab_Automation_Amafel-Calalay.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/09\/qPCR_GEN_Blog_AI_Lab_Automation_Amafel-Calalay.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/09\/qPCR_GEN_Blog_AI_Lab_Automation_Amafel-Calalay.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":19966,"url":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/multiplex-assay-optimization-qpcr\/","url_meta":{"origin":14325,"position":5},"title":"Building Better Multiplex Panels: Identifying Assay Interactions Early","author":"Ashleigh Barlow","date":"September 8, 2026","format":false,"excerpt":"Multiplex qPCR has transformed molecular research by enabling scientists to detect multiple targets in a single reaction. The benefits are clear: reduced sample consumption, lower costs, faster workflows, and more data from every experiment. However, designing successful multiplex assays isn't always straightforward. Traditionally, identifying problematic assay combinations required extensive wet-lab\u2026","rel":"","context":"In "Lab Tips and Tricks"","block_context":{"text":"Lab Tips and Tricks","link":"https:\/\/admin.acceleratingscience.com\/behindthebench\/lab-tips-and-tricks\/"},"img":{"alt_text":"For Research Use Only. Not for use in diagnostic procedures. \u00a9 2026 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.","src":"https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/09\/Header-banner-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/09\/Header-banner-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/09\/Header-banner-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/09\/Header-banner-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/09\/Header-banner-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/09\/Header-banner-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2020\/08\/AV1354-001-scaled.jpg","_links":{"self":[{"href":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/wp-json\/wp\/v2\/posts\/14325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/wp-json\/wp\/v2\/users\/120"}],"replies":[{"embeddable":true,"href":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/wp-json\/wp\/v2\/comments?post=14325"}],"version-history":[{"count":0,"href":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/wp-json\/wp\/v2\/posts\/14325\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/wp-json\/wp\/v2\/media\/14328"}],"wp:attachment":[{"href":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/wp-json\/wp\/v2\/media?parent=14325"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/wp-json\/wp\/v2\/categories?post=14325"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/wp-json\/wp\/v2\/tags?post=14325"},{"taxonomy":"division","embeddable":true,"href":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/wp-json\/wp\/v2\/division?post=14325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}